Gene Therapy for Bovine Fatty Liver : Possibilities and Problems - A Review

  • Chen, Daiwen (Institute of Animal Nutrition, Sichuan Agricultural University) ;
  • Grummer, Ric (Department of Dairy Science,University of Wisconsin-Madison)
  • Published : 2001.09.01


Dairy cows are prone to fatty liver during the time of periparturient. Despite of the extensive studies, etiology and solutions for fatty liver are still not well known.The liver synthesizes triglycerides (TG) using precursors from bloodstream and secretes TG in form of very low density lipoprotein (VLDL) into bloodstream for the utilization by peripheral tissues. When the amount of TG synthesis exceeds the amount of secretion in VLDL-TG, TG accumulation within the liver occurs. Hepatic VLDL assembly and secretion involve multi-biochemical events.The availabilities of apolipoprotein B (apoB), E (apoE), microsomal triglyceride transfer protein (MTP) and soluble low density lipoprotein (LDL) receptor are now believed to be some of the main regulators for hepatic VLDL assembly and secretion. Studies in transgenic animals show that overexpression of these proteins stimulates VLDL production and secretion, which provides a possibility for alleviating bovine fatty liver by gene therapy. However, many problems remain to be solved to attain this goal. This review focuses on the molecular mechanisms of hepatic VLDL assembly and secretion, and the possibilities and problems of applying the knowledges to solve bovine fatty liver by gene therapy.


VLDL;Fatty Liver;Gene Therapy;Bovine

Cited by

  1. Small Intestine and Liver Microsomal Triacylglycerol Transfer Protein in the Bovine and Rat: Effects of Dietary Coconut Oil vol.87, pp.11, 2004,